[1]程爱萍,陈绍亮.放射性核素治疗癌转移性骨痛[J].国际放射医学核医学杂志,2008,32(2):92-95.
　CHENG Ai-ping,CHEN Shao-liang.Radionuclide therapy of patients with metastastic bone pain[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(2):92-95.
点击复制

放射性核素治疗癌转移性骨痛(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
32
期数:
2008年第2期
页码:
92-95
栏目:
临床核医学
出版日期:
1900-01-01

文章信息/Info

Title:
Radionuclide therapy of patients with metastastic bone pain
作者:
程爱萍;  陈绍亮
200032 上海, 复旦大学核医学研究所, 复旦大学附属中山医院核医学科
Author(s):
CHENG Ai-ping;  CHEN Shao-liang
Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, Institute of Nuclear Medicine, Fudan University, Shanghai 200032, China
关键词:
镇痛; 病人控制; 近距离放射疗法; 癌转移性骨痛
Keywords:
Analgesia;  patient-controlled; Brachytherapy; Metastastic bone pain
摘要:
癌性骨转移原发病灶常见于前列腺癌、乳腺癌、肺癌等,转移发生的病理生理机制、疼痛机制目前不十分明确。止痛治疗尤其是对广泛骨转移性疼痛的治疗是临床医师面对的主要挑战,放射性核素及其标记药物治疗是一种有效、价廉、不良反应较小的治疗方法,对广泛转移的止痛治疗及微转移患者的治疗独具优势,目前有待充分利用。
Abstract:
Bone metastases are often the first sign of distant spread in breast, prostate, and lung cancers. The pathophysiology of bone metastasis is poorly understood and related complications is complex. Bone pain consequent to metastatic cancer continues to be a major therapeutic challenge for clinicians and its alleviation is crucial to improving the patient’s quality of life. Targeted radionuclide therapy is an effective and cost efficient treatment for multi-site metastatic bone pain, its advantages may also include therapy for subclinical micro-or oligometastatic disease before clinical manifestation. But radionuclides remain underutilized in such treatments.

参考文献/References:

[1] Yau V, Chow E, Davis L, et al. Pain management in cancer patients with bone metastases remains a challenge[J]. J Pain Symptom Manage, 2004, 27(1):1-3.
[2] Damerla V, Packianathan S, Boerner PS, et al.Recent developments in nuclear medicine in the management of bone metastases:a review and perspective[J]. Aria J Clin Oncol, 2005, 28(5):513-520.
[3] Jemal A, Murray T, Samuels A, et al. Cancer statistics[J]. CA Cancer J Clin, 2003, 53(1):5-26.
[4] Choong PF. The molecular basis of skeletal metastases[J], Clin Orthop Relat Res, 2003, (415 Suppl):S19-S31.
[5] Pandit-Taskar N, Batraki M, Divgi CIR. Radiopharmaceutical therapy for palliation of bone pain from osseous metastases[J]. J Nucl Med, 2004, 45(8):1358-1365.
[6] Lewington VJ. Bone-seeking radionuclides for therapy[J]. J Nucl Med, 2005, 46(suppl 1):38S-47S.
[7] Liepe K, Hliscs R, Kropp J, et al. Dosimetry of 188Re-hydroxyethylidenediphosphonate in human prostate cancer skeletal metastases[J]. J Nucl Med, 2003, 44(6):953-960.
[8] Pahnedo H, Manka-Waluch A, Albers P, et al. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma:randomized phase Ⅱ trial with the new, high-energy radiopharmaceutical rhenium-188h ydroxyethylidenediphosphonate[J]. J Clin Oncol, 2003, 21(15):2869-2875.
[9] Bishayee A, Rao DV, Srivastava SC, et al. Marrow-sparing effects of 117mSn (4+)diethylenetriaminepentaacetic acid for radionuclide therapy of bone cancer[J]. J Nucl Med, 2000, 41(12):2043-2050.
[10] Henriksen G, Fisher DR, Roeske JC, et al. Targeting of osseous sites with alpha-emitting 223Ra:comparison with the βemitter 89Sr in mice[J]. J Nucl Med, 2003,44(2):252-259.

备注/Memo

备注/Memo:
收稿日期:2007-09-15。
通讯作者:陈绍亮(E-mail:chen.shaoliang@zs-hospital.sh.cn)
更新日期/Last Update: 1900-01-01